Results 221 to 230 of about 284,607 (379)

Performative Reviews and Phantom Audiences

, 1969
Lynn Deboeck
openalex   +2 more sources

RKIP overexpression reduces lung adenocarcinoma aggressiveness and sensitizes cells to EGFR‐targeted therapies

Molecular Oncology, EarlyView.
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha, Joana Pinheiro, Rui F. Marques, Patrícia Fontão, Diana Cardoso‐Carneiro, Adriana Mendes, Izabela N. F. Gomes, Ana Carolina Laus, Renato J. da Silva‐Oliveira, Rui Manuel Reis, Olga Martinho   +10 more
wiley   +1 more source

New mesh-type phantoms and their dosimetric applications, including emergencies

Annals of the ICRP, 2018
Chan Hyeong Kim, Y. Yeom, T. Nguyen, M. Han, Chansoo Choi, Hanjin Lee, Haegin Han, B. Shin, Jai Ki Lee, Han Sung Kim, Maria Zankl, N. Petoussi-Henss, Wesley E. Bolch, Choonik Lee, B. Chung, Rui Qiu, K. Eckerman   +16 more
semanticscholar   +1 more source

Controlled localization of ultrasound heating using magnetic nanoparticle assemblies. [PDF]

Ultrason Sonochem
Ratajczak F, Prajwos E, Bielas R, Józefczak A.   +3 more
europepmc   +1 more source

Characterizing the salivary RNA landscape to identify potential diagnostic, prognostic, and follow‐up biomarkers for breast cancer

Molecular Oncology, EarlyView.
This study explores salivary RNA for breast cancer (BC) diagnosis, prognosis, and follow‐up. High‐throughput RNA sequencing identified distinct salivary RNA signatures, including novel transcripts, that differentiate BC from healthy controls, characterize histological and molecular subtypes, and indicate lymph node involvement.
Nicholas Rajan, Irina Primac, Emre Etlioglu, Laurens Debruyne, Ann Janssen, Magy Sallam, Kevin Tabury, Roel Quintens, Wiebren Tjalma, Mohammed Abderrafi Benotmane   +9 more
wiley   +1 more source

Characterization of tumour-like inclusions in breast-mimicking phantoms using ultrasound optical tomography. [PDF]

Sci Rep
Zabiliūtė-Karaliūnė A, Bukartė E, Ruchkina M, Kinos A, Bengtsson A, Hill D, Reistad N, Rippe L, Swartling J, Dravecz G, Lengyel K, Dustler M, Chaudhry N, Bakic PR, Zackrisson S, Kröll S.   +15 more
europepmc   +1 more source

Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology

Molecular Oncology, EarlyView.
Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts, Senada Koljenović, Elise Daems, Karolien De Wael, Marc Peeters, Léon C. van Kempen, Greetje Vanhoutte, Karen Zwaenepoel, Timon Vandamme   +8 more
wiley   +1 more source

Affordable miniaturized speckle contrast diffuse correlation tomography device for depth-sensitive mapping of cerebral blood flow in rodents. [PDF]

J Biomed Opt
Hamedi F, Akbari F, Mohtasebi M, Huang C, Chen L, Chen L, Yu G.   +6 more
europepmc   +1 more source

Phantom flowers,

openalex   +2 more sources

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source